CA3053238A1 - Aminobenzimidazole derivatives - Google Patents

Aminobenzimidazole derivatives Download PDF

Info

Publication number
CA3053238A1
CA3053238A1 CA3053238A CA3053238A CA3053238A1 CA 3053238 A1 CA3053238 A1 CA 3053238A1 CA 3053238 A CA3053238 A CA 3053238A CA 3053238 A CA3053238 A CA 3053238A CA 3053238 A1 CA3053238 A1 CA 3053238A1
Authority
CA
Canada
Prior art keywords
alkyl
compound
group
nhr
imidazol
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3053238A
Other languages
English (en)
French (fr)
Inventor
Tong Wang
Stephen Gately
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Translational Drug Development LLC
Original Assignee
Translational Drug Development LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Translational Drug Development LLC filed Critical Translational Drug Development LLC
Publication of CA3053238A1 publication Critical patent/CA3053238A1/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/24—Benzimidazoles; Hydrogenated benzimidazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C07D235/30—Nitrogen atoms not forming part of a nitro radical
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CA3053238A 2016-03-02 2016-05-23 Aminobenzimidazole derivatives Pending CA3053238A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662302781P 2016-03-02 2016-03-02
US62/302,781 2016-03-02
PCT/US2016/033841 WO2017151165A1 (en) 2016-03-02 2016-05-23 Aminobenzimidazole derivatives

Publications (1)

Publication Number Publication Date
CA3053238A1 true CA3053238A1 (en) 2017-09-08

Family

ID=59744272

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3053238A Pending CA3053238A1 (en) 2016-03-02 2016-05-23 Aminobenzimidazole derivatives

Country Status (8)

Country Link
US (1) US20190040017A1 (https=)
EP (1) EP3423439A4 (https=)
JP (1) JP6768078B2 (https=)
CN (1) CN109071460B (https=)
AU (1) AU2016394945A1 (https=)
CA (1) CA3053238A1 (https=)
IL (1) IL261201B (https=)
WO (1) WO2017151165A1 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2015217788B2 (en) 2014-02-11 2019-06-27 Deutsches Krebsforschungszentrum, Stiftung Des Öffentlichen Rechts Benzimidazol-2-amines as mIDH1 inhibitors
CN105980365B (zh) 2014-02-11 2019-06-21 拜耳医药股份公司 作为mIDH1抑制剂的苯并咪唑-2-胺
EP3544601B1 (en) * 2016-11-23 2024-03-20 Translational Drug Development, LLC A composition comprising a benzamide and a tnfrsf agonist binding to 4-1bb or gitr, and the use thereof in the treatment of cancer.
JP2020533316A (ja) * 2017-09-06 2020-11-19 トランスレイショナル・ドラッグ・ディベロップメント・エルエルシー アミノベンゾイミダゾール誘導体、治療、およびヒストン脱アセチル化酵素を阻害する方法
WO2023002246A1 (en) * 2021-07-21 2023-01-26 Carna Biosciences, Inc. Novel 1,2-diaminobenzimidazole derivative

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090048252A1 (en) * 2006-03-02 2009-02-19 Smithkline Beecham Corporation Thiazolones for use as pi3 kinase inhibitors
AU2010263113B2 (en) * 2009-06-23 2015-11-26 Translational Drug Development, Llc Benzamide derivatives
WO2012166569A1 (en) * 2011-05-27 2012-12-06 Cisco Technology, Inc. Precision timing in a data over cable service interface specification (docsis) system
HK1214552A1 (zh) * 2012-11-05 2016-07-29 细胞基因公司 在腎損傷的受試者中用泊馬度胺治療癌症
WO2016191397A1 (en) * 2015-05-22 2016-12-01 Td2 Inc. Benzamide and active compound compositions and methods of use
WO2017009325A1 (en) * 2015-07-16 2017-01-19 Bayer Pharma Aktiengesellschaft 5-hydroxyalkylbenzimidazoles as midh1 inhibitors

Also Published As

Publication number Publication date
EP3423439A1 (en) 2019-01-09
US20190040017A1 (en) 2019-02-07
JP6768078B2 (ja) 2020-10-14
JP2019511485A (ja) 2019-04-25
IL261201A (en) 2018-10-31
CN109071460A (zh) 2018-12-21
AU2016394945A1 (en) 2018-10-11
IL261201B (en) 2022-01-01
EP3423439A4 (en) 2019-08-14
CN109071460B (zh) 2022-08-09
WO2017151165A1 (en) 2017-09-08

Similar Documents

Publication Publication Date Title
US10590088B2 (en) 4-(benzimidazol-2-ylamino)benzamide derivatives and methods of synthesis thereof
US8987468B2 (en) Compounds, pharmaceutical compositions and methods of use of hydroxamic acid derivatives
US9221773B2 (en) Benzamide derivatives
US20190040017A1 (en) Aminobenzimidazole derivatives
US11780816B2 (en) Aminobenzimidazole derivatives, treatments, and methods of inhibiting histone deacetylase
HK1260272B (en) Aminobenzimidazole derivatives
HK1260272A1 (en) Aminobenzimidazole derivatives
HK40026716A (en) Aminobenzimidazole derivatives, treatments, and methods of inhibiting histone deacetylase
HK1204227B (en) Benzamide derivatives

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20210520

D15 Examination report completed

Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D15-D126 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S REPORT

Effective date: 20250313

B12 Application deemed to be withdrawn, abandoned or lapsed

Free format text: ST27 STATUS EVENT CODE: N-6-6-B10-B12-B303 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: DEEMED ABANDONED - FAILURE TO RESPOND TO AN EXAMINER'S REQUISITION

Effective date: 20250714

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20251203

U13 Renewal or maintenance fee not paid

Free format text: ST27 STATUS EVENT CODE: N-2-6-U10-U13-U300 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: DEEMED ABANDONED - FAILURE TO RESPOND TO MAINTENANCE FEE NOTICE

Effective date: 20260203